Abstract：
:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is inadequate), and the risk of transfusion-related infection is decreased. Nevertheless, rHuEpo is relatively expensive (a 6-week course costs approximately the same as 2 blood transfusions), so its use requires careful consideration; it is logical to target rHuEpo therapy to those babies who are most likely to be transfused. Using this strategy, 1 study involving stable growing preterm infants has shown that direct costs of blood transfusion and rHuEpo were similar, and the use of rHuEpo was recommended. In addition, use of high-dosage rHuEpo early in the course of management on the neonatal intensive care unit has been shown to reduce direct treatment costs in ill preterm infants. Further studies will continue to identify infants who are likely to benefit from rHuEpo therapy and to define its cost effectiveness in more detail.
journal_name
Pharmacoeconomicsjournal_title
PharmacoEconomicsauthors
Meyer MPdoi
10.2165/00019053-199712040-00002subject
Has Abstractpub_date
1997-10-01 00:00:00pages
438-45issue
4eissn
1170-7690issn
1179-2027journal_volume
12pub_type
杂志文章,评审abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/11310110-000000000-00000
更新日期：2009-01-01 00:00:00
abstract：:Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-199712060-00008
更新日期：1997-12-01 00:00:00
abstract：:The National Institute for Health and Care Excellence (NICE) invited GlaxoSmithKline, the manufacturer of dabrafenib, to submit evidence for the clinical and cost effectiveness of dabrafenib for the treatment of unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma in accordance with the Institute'...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-015-0276-9
更新日期：2015-09-01 00:00:00
abstract：BACKGROUND:To reach the French market, a new drug requires a marketing authorization (MA) and price and reimbursement agreements. These hurdles could delay access to new and promising drugs. Since 1992, French law authorizes the use of unlicensed drugs on an exceptional and temporary basis through a compassionate-use p...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-013-0039-4
更新日期：2013-04-01 00:00:00
abstract：:Vaccination is an underutilised, low cost and effective method of preventing illness. Cost-effectiveness analysis discloses a beneficial role of influenza vaccination in preventing illness especially in patients over 65 years of age and in high risk patients. In one large study, when 150 million doses of influenza v...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-199202030-00003
更新日期：1992-09-01 00:00:00
abstract：:The aim of this article was to perform a detailed methodological review of models used to estimate the cost effectiveness of drug treatment regimens for HIV infection in Europe and North America and assess the relationship between the different modeling approaches or key structural assumptions and the results. Electro...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-013-0098-6
更新日期：2013-11-01 00:00:00
abstract：BACKGROUND:Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-020-00954-y
更新日期：2020-12-01 00:00:00
abstract：:Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated prevalence rate in the general population of 10-15% in industrialised countries. Although IBS is not a life-threatening disease, it contributes significantly to a large segment of healthcare resource consu...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200624010-00002
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:In Australia, many patients who are initiated on asthma controller inhalers receive combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) despite having asthma of sufficiently low severity that ICS-alone would be equally effective and less costly for the government. METHODS:We conducted a ...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-018-0731-5
更新日期：2019-02-01 00:00:00
abstract：:About one-quarter of men aged 50 years and older experience voiding problems due to benign prostatic hyperplasia (BPH). Until about 10 years ago, surgery (particularly transurethral resection of the prostate) was the only effective treatment for symptomatic BPH. Over the last decade, several new treatments have been i...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200119020-00003
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0312-9
更新日期：2015-10-01 00:00:00
abstract：BACKGROUND:The high consumption of hypolipidaemic agents warrants the study of the costs caused by these medicines being inadequately prescribed. OBJECTIVE:To quantify the economic cost generated in 1 year in primary care by inadequate (or unnecessary) prescriptions for hypolipidaemic drugs. METHODS:A cross-sectional...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200119050-00006
更新日期：2001-01-01 00:00:00
abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...
journal_title：PharmacoEconomics
pub_type： 杂志文章,meta分析,评审
doi：10.2165/00019053-200927030-00003
更新日期：2009-01-01 00:00:00
abstract：:Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...
journal_title：PharmacoEconomics
pub_type： 已发布勘误
doi：10.1007/s40273-018-0754-y
更新日期：2019-02-01 00:00:00
abstract：BACKGROUND:Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE:The aim o...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0305-8
更新日期：2015-11-01 00:00:00
abstract：:Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article. ...
journal_title：PharmacoEconomics
pub_type： 已发布勘误
doi：10.1007/s40273-019-00857-7
更新日期：2020-01-01 00:00:00
abstract：BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0324-5
更新日期：2016-01-01 00:00:00
abstract：:Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indic...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-017-0599-9
更新日期：2018-04-01 00:00:00
abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-018-0677-7
更新日期：2018-12-01 00:00:00
abstract：BACKGROUND:Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). OBJECTIVE:To identify and develop a taxonomic account of economic modellin...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-016-0460-6
更新日期：2017-02-01 00:00:00
abstract：:This century has seen a phenomenal growth in the development, understanding and use of pharmaceuticals. Additionally, this period has seen the balance of the treatment needs of patients shift dramatically from infectious to cardiovascular and cancer diseases, and from infancy and middle-age to old age. The value of mo...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-199813060-00001
更新日期：1998-06-01 00:00:00
abstract：:An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199610060-00006
更新日期：1996-12-01 00:00:00
abstract：:The purpose of this paper is to highlight important considerations in the measurement of health-related quality of life (HR-QOL) in paediatric populations. Considerations specific to the evaluation of HR-QOL in children include children's understanding of the questions being asked, their understanding of their own dis...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199916060-00002
更新日期：1999-12-01 00:00:00
abstract：:Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199507030-00004
更新日期：1995-03-01 00:00:00
abstract：:The manufacturer of olaratumab (Lartruvo®), Eli Lilly & Company Limited, submitted evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for untreated advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy, as part of the National Institute for Health and C...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-017-0568-3
更新日期：2018-01-01 00:00:00
abstract：:Patients with schizophrenia suffer numerous relapses and rehospitalizations that are associated with high direct and indirect medical expense. Suboptimal therapeutic efficacy and, in particular, problems with compliance are major factors leading to relapse. Atypical antipsychotic agents offer improved efficacy and a l...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200523001-00004
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Given the limited availability of healthcare resources and the recent introduction of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in postmenopausal osteoporosis remains and even increases. OBJECTIVE:This study aims to identify all recent economic evaluations on drugs for pos...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-014-0231-1
更新日期：2015-03-01 00:00:00
abstract：:The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (a...
journal_title：PharmacoEconomics
pub_type： 临床试验,杂志文章,多中心研究
doi：10.2165/00019053-199700111-00005
更新日期：1997-01-01 00:00:00
abstract：OBJECTIVE:The aim of the study was to determine the costs and effects associated with a community pharmacy-based smoking-cessation programme in Northern Ireland, using the perspective of the payer in the main analysis. DESIGN AND SETTING:Data from a pilot study conducted in 2 community pharmacies in Northern Ireland w...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-199814030-00008
更新日期：1998-09-01 00:00:00
abstract：:Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200220150-00002
更新日期：2002-01-01 00:00:00
